Last quarter (Q3 2023), Petros Pharmaceuticals's total revenue was $1.67M, a decrease of -214.88% from the same quarter last year. In Q3, Petros Pharmaceuticals's net income was $-4.89M. See Petros Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 4.07M	$ 5.99M	$ 7.81M	$ 9.56M	$ 15.58M
Cost of Revenue	$ -1.28M	$ 2.29M	$ -1.60M	$ 4.05M	$ 7.43M
Gross Profit	$ 1.71M	$ 3.70M	$ 6.21M	$ 5.51M	$ 8.15M
Operating Expense	$ -17.52M	$ 16.16M	$ -24.26M	$ 22.80M	$ 25.02M
Operating Income	$ -15.58M	$ -12.46M	$ -8.99M	$ -17.28M	$ -16.87M
Net Non Operating Interest Income Expense	$ -627.50K	$ -581.82K	$ 368.66K	$ -3.05M	$ -13.84M
Other Income Expense	$ -11.31M	$ 7.00M	-	$ -1.68M	$ -2.44M
Pretax Income	$ -15.88M	$ -20.04M	$ -8.99M	$ -22.01M	$ -33.16M
Tax Provision	$ -10.50K	-	-	$ -1.43M	$ -645.87K
Earnings From Equity Interest Net Of Tax	$ 460.00K	-	-	-	-
Net Income Common Stockholders	$ -16.09M	$ -20.04M	$ -8.99M	$ -20.59M	$ -32.51M
Basic EPS	$ -13.08	$ -9.68	$ -0.83	$ -3.85	$ -3.35
Diluted EPS	$ -13.08	$ -9.68	$ -0.83	$ -3.85	$ -3.35
Basic Average Shares	$ 8.40M	$ 2.07M	$ 10.89M	$ 5.34M	$ 9.71M
Diluted Average Shares	$ 8.40M	$ 2.07M	$ 10.89M	$ 5.34M	$ 9.71M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ -18.80M	$ 18.45M	$ -25.86M	$ 26.84M	$ 32.45M
Net Income From Continuing And Discontinued Operation	$ -15.62M	$ -20.04M	$ -8.99M	$ -20.59M	$ -32.51M
Normalized Income	$ -5.58M	-	-	$ -19.01M	$ -30.12M
Interest Expense	-	-	-	$ 3.05M	$ 13.84M
EBIT	$ -15.25M	$ -19.44M	$ -9.71M	$ -18.96M	$ -19.31M
EBITDA	$ -12.01M	$ -13.84M	$ -2.82M	$ -12.30M	$ -14.02M

Currency in USD

Petros Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing